Literature DB >> 26494960

Posttransplant lymphoproliferative disorders following liver transplantation: Where are we now?

Daan Dierickx1, Nina Cardinaels1.   

Abstract

Liver transplantation has emerged as a life-saving treatment for several patients with acute liver failure, end stage liver disease and primary hepatic malignancies. However, long term immunosuppressive therapy aiming to reduce the risk of transplant rejection increases the incidence of several complications including malignancies. This is illustrated by the observation of a high ratio between observed and expected cases of lymphoproliferative disorders following liver transplantation. Despite a huge heterogeneity in morphological appearance of these disorders ranging from reactive-like lesions to real lymphomas, they are collectively termed posttransplant lymphoproliferative disorders. In this review we will provide an overview of this rare but challenging disorder as a complication of liver transplantation.

Entities:  

Keywords:  Epstein Barr virus; Liver transplantation; Posttransplant lymphoproliferative disorders

Mesh:

Substances:

Year:  2015        PMID: 26494960      PMCID: PMC4607903          DOI: 10.3748/wjg.v21.i39.11034

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  68 in total

1.  Hypothesis: a novel route for immortalization of epithelial cells by Epstein-Barr virus.

Authors:  Yanning Gao; Yong-Jie Lu; Shao-An Xue; Honglin Chen; Nina Wedderburn; Beverly E Griffin
Journal:  Oncogene       Date:  2002-01-24       Impact factor: 9.867

Review 2.  The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders.

Authors:  Anna Merlo; Riccardo Turrini; Riccardo Dolcetti; Debora Martorelli; Elena Muraro; Patrizia Comoli; Antonio Rosato
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

3.  Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).

Authors:  S H K Oertel; E Verschuuren; P Reinke; K Zeidler; M Papp-Váry; N Babel; R U Trappe; S Jonas; M Hummel; I Anagnostopoulos; B Dörken; H B Riess
Journal:  Am J Transplant       Date:  2005-12       Impact factor: 8.086

4.  CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients.

Authors:  M Green; M G Michaels; B Z Katz; M Burroughs; D Gerber; B L Shneider; K Newell; D Rowe; J Reyes
Journal:  Am J Transplant       Date:  2006-08       Impact factor: 8.086

5.  Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation.

Authors:  D W Hanto; G Frizzera; K J Gajl-Peczalska; K Sakamoto; D T Purtilo; H H Balfour; R L Simmons; J S Najarian
Journal:  N Engl J Med       Date:  1982-04-15       Impact factor: 91.245

6.  International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial.

Authors:  R U Trappe; S Choquet; D Dierickx; P Mollee; J M Zaucha; M H Dreyling; U Dührsen; C Tarella; O Shpilberg; M Sender; G Salles; F Morschhauser; A Jaccard; T Lamy; P Reinke; R Neuhaus; H Lehmkuhl; H A Horst; M Leithäuser; P Schlattmann; I Anagnostopoulos; M Raphael; H Riess; V Leblond; S Oertel
Journal:  Am J Transplant       Date:  2015-03-03       Impact factor: 8.086

7.  Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation.

Authors:  C Hézode; C Duvoux; G Germanidis; F Roudot-Thoraval; A L Vincens; P Gaulard; D Cherqui; J M Pawlotsky; D Dhumeaux
Journal:  Hepatology       Date:  1999-09       Impact factor: 17.425

8.  Impact of immunosuppression on the development of Epstein-Barr virus (EBV) viremia after pediatric liver transplantation.

Authors:  B R Lu; K T Park; M Hurwitz; K L Cox; W E Berquist
Journal:  Transplant Proc       Date:  2012-09-06       Impact factor: 1.066

9.  Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution.

Authors:  Sylvain Choquet; Stephan Oertel; Veronique LeBlond; Hanno Riess; Nathalie Varoqueaux; Bernd Dörken; Ralf Trappe
Journal:  Ann Hematol       Date:  2007-05-24       Impact factor: 3.673

10.  Outcome of rapamycin therapy for post-transplant-lymphoproliferative disorder after kidney transplantation: case series.

Authors:  Farzaneh Ashrafi; Shahrzad Shahidi; Zeinab Ebrahimi; Mojgan Mortazavi
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2015-01-01
View more
  3 in total

1.  Post-transplant lymphoproliferative disorders in a cohort of adult patients with a liver transplant from a reference hospital in Bogotá, Colombia

Authors:  Leonardo F Jurado; Andrés Gómez-Aldana; Mónica Tapias; Daniela Cáceres; Alonso Vera; Rocío Del Pilar López-Panqueva; Rafael E Andrade
Journal:  Biomedica       Date:  2020-09-01       Impact factor: 0.935

2.  Early Onset Post-transplant Lymphoproliferative Disorder Presenting with Diarrhea Post-orthotopic Liver Transplant Treated Successfully with Single Rituximab Agent.

Authors:  Bonnie Patek; Cristina Strahotin
Journal:  Cureus       Date:  2019-11-19

3.  Pretransplant Hepatic Malignancy Increases Risk of De Novo Malignancy after Liver Transplantation.

Authors:  Gil Chun Park; Shin Hwang; Chul Soo Ahn; Ki Hun Kim; Deok Bog Moon; Tae Yong Ha; Gi Won Song; Dong Hwan Jung; Young In Yoon; Hui Dong Cho; Jae Hyun Kwon; Yong Kyu Chung; Sang Hyun Kang; Jin Uk Choi; I Ji Jung; Sung Gyu Lee
Journal:  J Korean Med Sci       Date:  2020-03-23       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.